Suppr超能文献

用于靶向金属蛋白酶的螯合剂片段文库。

Chelator fragment libraries for targeting metalloproteinases.

机构信息

Department of Chemistry and Biochemistry, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.

出版信息

ChemMedChem. 2010 Feb 1;5(2):195-9. doi: 10.1002/cmdc.200900516.

Abstract

A chelator fragment library based on a variety of metal binding groups was screened against a metalloproteinase. Lead hits were identified and an expanded library of select compounds was synthesized, resulting in numerous high-affinity hits against several metalloprotein targets. The findings clearly demonstrate that chelators can be used to generate libraries suitable for fragment-based lead design (FBLD) directed at important metalloproteins.

摘要

基于多种金属结合基团的螯合剂片段库针对金属蛋白酶进行了筛选。鉴定出先导化合物,并合成了选择化合物的扩展文库,得到了针对几种金属蛋白酶靶标的许多高亲和力化合物。研究结果清楚地表明,螯合剂可用于生成适用于基于片段的先导设计(FBLD)的文库,以针对重要的金属蛋白酶。

相似文献

1
Chelator fragment libraries for targeting metalloproteinases.
ChemMedChem. 2010 Feb 1;5(2):195-9. doi: 10.1002/cmdc.200900516.
2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
J Med Chem. 2011 Jan 27;54(2):591-602. doi: 10.1021/jm101266s. Epub 2010 Dec 28.
3
A new role for old ligands: discerning chelators for zinc metalloproteinases.
J Am Chem Soc. 2006 Mar 15;128(10):3156-7. doi: 10.1021/ja057957s.
4
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.
Bioorg Med Chem. 2008 Oct 1;16(19):8781-94. doi: 10.1016/j.bmc.2008.08.058. Epub 2008 Aug 29.
6
Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors.
J Med Chem. 2017 Jul 13;60(13):5816-5825. doi: 10.1021/acs.jmedchem.7b00514. Epub 2017 Jun 27.
9
Inhibition of botulinum neurotoxin BoNT/A.
Curr Top Med Chem. 2014;14(18):2043. doi: 10.2174/1568026614666141022095612.
10
Investigating chelating sulfonamides and their use in metalloproteinase inhibitors.
Dalton Trans. 2012 Jun 7;41(21):6507-15. doi: 10.1039/c2dt12373h. Epub 2012 Mar 12.

引用本文的文献

2
ChemFH: an integrated tool for screening frequent false positives in chemical biology and drug discovery.
Nucleic Acids Res. 2024 Jul 5;52(W1):W439-W449. doi: 10.1093/nar/gkae424.
3
MolProphet: A One-Stop, General Purpose, and AI-Based Platform for the Early Stages of Drug Discovery.
J Chem Inf Model. 2024 Apr 22;64(8):2941-2947. doi: 10.1021/acs.jcim.3c01979. Epub 2024 Apr 2.
8
E3 Ligases Meet Their Match: Fragment-Based Approaches to Discover New E3 Ligands and to Unravel E3 Biology.
J Med Chem. 2023 Mar 9;66(5):3173-3194. doi: 10.1021/acs.jmedchem.2c01882. Epub 2023 Feb 23.
9
Hydroxypyrone derivatives in drug discovery: from chelation therapy to rational design of metalloenzyme inhibitors.
RSC Med Chem. 2022 Jul 29;13(10):1127-1149. doi: 10.1039/d2md00175f. eCollection 2022 Oct 19.
10
Fragment screening at AstraZeneca: developing the next generation biophysics fragment set.
RSC Med Chem. 2022 Jul 4;13(9):1052-1057. doi: 10.1039/d2md00154c. eCollection 2022 Sep 21.

本文引用的文献

3
Recent developments in fragment-based drug discovery.
J Med Chem. 2008 Jul 10;51(13):3661-80. doi: 10.1021/jm8000373. Epub 2008 May 6.
4
Zinc-binding groups modulate selective inhibition of MMPs.
ChemMedChem. 2008 May;3(5):812-20. doi: 10.1002/cmdc.200700290.
5
A high-throughput screening approach to anthrax lethal factor inhibition.
Bioorg Chem. 2007 Aug;35(4):306-12. doi: 10.1016/j.bioorg.2006.12.005. Epub 2007 Feb 22.
6
The design of inhibitors for medicinally relevant metalloproteins.
ChemMedChem. 2007 Feb;2(2):152-71. doi: 10.1002/cmdc.200600204.
7
Fragment-based drug design: how big is too big?
J Med Chem. 2006 Nov 30;49(24):6972-6. doi: 10.1021/jm060511h.
8
A library of novel hydroxamic acids targeting the metallo-protease family: design, parallel synthesis and screening.
Bioorg Med Chem. 2007 Jan 1;15(1):63-76. doi: 10.1016/j.bmc.2006.10.010. Epub 2006 Oct 12.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验